Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

124

Enrollment

INDUSTRY

Sponsor class

Stopped Closed for administrative, non-safety-related reasons.

Conditions

Healthy (For Part A)
Chronic Myeloid Leukemia (for Part B and C)

Interventions

DRUG: Vodobatinib (K0706) capsules

Sponsor

Sun Pharma Advanced Research Company Limited